MedTrace Logo

Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

NCT05811442 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-09-18

No results posted yet for this study

Summary

This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's disease.

Conditions

Interventions

DRUG

50561 high dose

study drug

DRUG

50561 low dose

study drug

DRUG

Placebo

Non-active study drug

Sponsors & Collaborators

  • Beijing Joekai Biotechnology LLC

    lead INDUSTRY

Principal Investigators

  • Jianping Jia · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-18
Primary Completion
2025-08-22
Completion
2025-09-11

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05811442 on ClinicalTrials.gov